MDT-AP-1185
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 12.96
- os_event
- false
- age_years
- 15
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.562053386
- umap2_2d
- -9.425829491
- umap1_3d
- -2.921806115
- umap2_3d
- -1.708602927
- umap3_3d
- 5.071458189
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- MTORC1_SIGNALING+0.450
- OXIDATIVE_PHOSPHORYLATION+0.420
- INTERFERON_ALPHA_RESPONSE+0.410
- ANGIOGENESIS+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.370
- GLYCOLYSIS+0.350
Top 10 suppressed
- KRAS_SIGNALING_DN-0.160
- MITOTIC_SPINDLE-0.160
- HEDGEHOG_SIGNALING-0.140
- HEME_METABOLISM-0.060
- WNT_BETA_CATENIN_SIGNALING-0.010
- SPERMATOGENESIS+0.020
- UV_RESPONSE_DN+0.020
- KRAS_SIGNALING_UP+0.030
- PI3K_AKT_MTOR_SIGNALING+0.040
- TGF_BETA_SIGNALING+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.926 |
| 2 | MDT-AP-2822 | Med | Medulloblastoma | 0.925 |
| 3 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.923 |
| 4 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.915 |
| 5 | MDT-AP-0428 | Med | Medulloblastoma | 0.912 |
| 6 | MDT-AP-1381 | Med | Medulloblastoma | 0.911 |
| 7 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.910 |
| 8 | MDT-AP-2001 | Med | Medulloblastoma | 0.907 |
| 9 | BS_RSRPX3S8 | Med | Medulloblastoma | 0.905 |
| 10 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |